Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 14/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756417 | 0.86 | MRGPRX4 (0.73) | CCR5MRGPRX4 | |
| SCHEMBL5700075 | 0.83 | CCR5 (0.71) | CCR5MRGPRX4LOXL2CYP4F2CYP4A11 | |
| SCHEMBL9368832 | 0.80 | MRGPRX4 (0.73) | MRGPRX4LOXL2NPC1ALDH1A1TP53 | |
| SCHEMBL31160279 | 0.80 | MRGPRX4 (0.58) | CCR5MRGPRX4LOXL2CYP4F2CYP4A11 | |
| SCHEMBL1756350 | 0.79 | MRGPRX4 (0.51) | CCR5MRGPRX4NPC1ALDH1A1TP53 | |
| SCHEMBL1756395 | 0.78 | MRGPRX4 (0.70) | MRGPRX4LOXL2NPC1ALDH1A1TP53 | |
| SCHEMBL31160402 | 0.78 | MRGPRX4 (0.59) | MRGPRX4LOXL2CYP4F2CYP4A11NPC1 | |
| SCHEMBL22469846 | 0.78 | MRGPRX4 (0.76) | MRGPRX4 | |
| SCHEMBL2706579 | 0.78 | MRGPRX4 (0.57) | CCR5MRGPRX4LOXL2CYP4F2CYP4A11 | |
| SCHEMBL1756352 | 0.77 | MRGPRX4 (0.51) | MRGPRX4NPC1ALDH1A1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | disclosed |
| WO-2011058154-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058154-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | disclosed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | CCR5 4003/4885MRGPRX4 3745/4885LOXL2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.